Which drug should be used to treat patients with uncomplicated essential hypertension?

Current Opinion in Nephrology and Hypertension

Volumn 15, Issue 3, 2006, Pages 303-308

  Rashidi, Arash ^a   Rahman, Mahboob ^a   Wright Jr , Jackson T ^a,b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Antihypertensive therapy; Clinical outcome trials; Guidelines; Hypertension

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; ISRADIPINE; LISINOPRIL; LOSARTAN; NIFEDIPINE; PERINDOPRIL; THIAZIDE DIURETIC AGENT; VALSARTAN; VERAPAMIL;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG USE; ESSENTIAL HYPERTENSION; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STROKE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC;

EID: 33646781251     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mnh.0000222699.37830.c7     Document Type: Review

References (28)

1. Ezzati M, Lopez AD, Rodgers A, et al. Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360:1347-1360.
2. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet 2003; 362:1527-1535.
3. Wright JT Jr, Bakris G, Greene T, et al., for the AASK Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial. JAMA 2002; 288:2421-2431.
4. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997; 277:739-745.
5. Collins R, Peto R, Godwin J, MacMahon S. Blood pressure and coronary heart disease. Lancet 1990; 336:370-371.
6. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J (Clin Res Ed) 1985; 291:97-104.
7. Probstfield JL, Applegate WB, Borhani NO, et al. The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group. Clin Exp Hypertens A 1989; 11:973-989.
8. Perry HM Jr, Bingham S, Horney A, et al. Antihypertensive efficacy of treatment regimens used in Veterans Administration hypertension clinics. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Hypertension 1998; 31:771-779.
9. Wright JT Jr, Dunn JK, Cutler JA, et al., for the ALLHAT Collaborative Research Group. Outcomes in hypertensive Blacks and non-Blacks treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005; 293:1595-1608. Largest comparison of newer agents versus thiazide diuretics in a multi-ethnic population.
10. Dahlof B, Sever PS, Poulter NR, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906. Large clinical outcome trial comparing a CCB with a β-blocker.
11. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366-372.
12. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003; 362:1527-1535.
13. Hypertension Management Guide for Doctors 2004. National Heart Foundation; 2004. www.heartfoundation.com.au/downloads/ hypertension_management_guide_2004.pdf. [Accessed 4 October 2005]
14. 2005 Canadian recommendations for the management of hypertension. http://www.hypertension.ca/Documentation/Recommendation05va.pdf. [Accessed 4 October 2005]
15. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Cardiology Guidelines for the management of Arterial Hypertension. J Hypertens 2003; 21:1011-1053.
16. Williams B, Poulter NR, Brown MJ, et al. The BHS Guidelines Working Party Guidelines for Management of Hypertension: report of the Fourth Working Party of the British Hypertension Society, 2004 - BHS IV. J Hum Hypertens 2004; 18:139-185.
17. Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
18. Whitworth JA. World Health Organization, International Society of Hypertension Writing Group 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21:1983-1992.
19. Hansson L, Lindholm LH, Niskanen L, et al. for the Captopril Prevention Project (CAPPP) study group. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611-616.
20. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751-1756.
21. Hansson L, Hedner T, Lung-Johansen P, et al. for the NORDIL Study Group. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356:359-365.
22. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
23. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583-592.
24. Black HR, Elliott WJ, Grandits G, et al. CONVINCE Research Group. Principal results of the Controlled Onset Verapamil. Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003; 289:2073-2082.
25. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000; 356:1955-1964.
26. Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care 2004; 27:247-255.
27. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43:963-969.
28. Kostis JB, Wilson AC, Freudenberger RS, et al. SHEP Collaborative Research Group. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005; 95:29-35.